Precision Sports Medicine Uses DNA and Wearables to Maximize Athlete Performance

Sports medicine has historically relied on population-level evidence, but mounting research shows that individual genetic, physiological, and molecular differences dramatically alter how athletes respond to training, injury, and treatment. This 2025 narrative review from authors at Harvard Medical School, Mayo Clinic, and University of Split synthesizes the current state of precision sports medicine, covering genomics, pharmacogenomics, digital health, and multi-omics—providing a practical framework for clinicians working with athletes at any level.

The review highlights that genetic factors account for approximately 66% of variability in athletic ability and status, a figure that underscores why population-average recommendations may miss the mark for individual athletes. Key endurance-related gene variants include AMPD1 (rs17602729 C) and PPARGC1A (rs8192678 G), which influence muscle fiber type, hemoglobin mass, and VO2 max. Power performance correlates with ACTN3 (rs1815739 C) and NOS3 (rs2070744 T) variants affecting testosterone signaling, muscle characteristics, and reaction time. Strength is modulated by PPARG (rs1801282 G), influencing muscle hypertrophy and fiber type distribution. These findings suggest that genetic profiling—now achievable via a simple cheek swab at relatively low cost—could meaningfully inform training program design.

Injury susceptibility is another domain where genomics shows clinical promise. COL5A1 (rs13946), involved in collagen synthesis and tendon strength, and MMP3 variants (rs591058, rs679620), governing tissue remodeling and repair, show strong correlations with competitive injury risk. ACTN3 (rs1815739), ACAN (rs1516797), and VEGFA (rs2010963) have been replicated across studies as predictors of non-contact injury susceptibility, linked to muscle fiber composition, cartilage structure, and angiogenesis respectively. GDF5, AMPD1, COL5A1, and IGF2 variants have additionally been connected to decreased match participation due to injury. For cardiac safety—a critical concern in elite sport—HCM mutations in MYH7, MYBPC3, and TNNT2 account for 35% of confirmed sudden cardiac death cases in the U.S., while KCNQ1 and KCNH2 mutations underlie long-QT syndrome, the leading electrical cause of sudden cardiac death.

Pharmacogenomics receives dedicated attention as a tool for optimizing medication management in athletes. CYP2C9 variants alter NSAID metabolism, affecting both efficacy and adverse effect profiles for drugs like ibuprofen. CYP2D6 variants influence opioid processing, while SLCO1B1 and CYP2C19 variants are relevant to cardiovascular drug pharmacokinetics. The review argues that pre-treatment PGx profiling can reduce adverse drug reactions, guide dosing, and shorten recovery timelines—a tangible benefit when every day off the field has career consequences.

Digital health and multi-omics round out the framework. Wearable sensors, mobile health apps, and centralized athlete management systems now allow real-time physiological monitoring that can flag readiness deficits or emerging injury risk before clinical symptoms appear. Multi-omics—integrating genomics, proteomics, metabolomics, and epigenomics—provides a molecular landscape that can inform personalized nutrition, supplementation, and training load decisions simultaneously. Early studies have identified distinct multi-omic signatures in elite athletes, though this remains an emerging area requiring larger, prospective validation. The authors acknowledge that the evidence base is still limited by small sample sizes, single-population recruitment, and the complexity of gene–environment interactions, calling for multi-ethnic cohort studies and greater integration of environmental variables like nutrition and psychosocial stress.